INTRODUCTION
============

Tuberculosis (TB) is a major global public health problem and one of the leading infectious causes of death. According to a recent WHO report, 1.6 million people worldwide died of TB in 2005.[@B1] Korea has shown a higher prevalence of mycobacterial infection than most of the other developed countries, and the prevalence of non-tuberculous mycobacterium (NTM) infection has increased in the developed countries.[@B2] Therefore, an increased emphasis has currently been placed on the rapid identification of *Mycobacterium tuberculosis* (MTB) and NTM.[@B2],[@B3]

The introduction of the nucleic acid amplification techniques has been one of the major developments in diagnosis of mycobacterium, and real-time PCR has recently been proposed for the detection.[@B4] Real-time PCR has several advantages, such as a short turnaround time, a low contamination rate due to the use of a closed system and the ability to quantify the bacterial load.[@B4],[@B5] In Korea, two real-time PCR kits that simultaneously detect MTB and NTM have been developed for rapid MTB detection and NTM discrimination. However, it is unclear whether these real-time PCR kits offer the same sensitivity and specificity as conventional PCR. In this study, we evaluated the diagnostic performance of three real-time PCR kits, by comparing the results from these kits with those from our in-house PCR and the conventional qualitative PCR techniques. The discrepant results were confirmed by DNA sequencing and genotyping chip analyses.

MATERIALS AND METHODS
=====================

Subjects
--------

This study was conducted at Kyung Hee Medical Center, Seoul, Korea from September 2009 to October 2009, using 91 clinical specimens and 37 provided DNA samples ([Table 1](#T1){ref-type="table"}). The clinical specimens contained pulmonary and extrapulmonary specimens, and the smear positive and negative specimens ([Table 2](#T2){ref-type="table"}). The specimens were stored at - 70℃ in the state of extracted DNA.

Specimen Preparation and DNA Separation
---------------------------------------

### In-house PCR, the AdvanSure TB/NTM real-time PCR kit (LG Lifescience, Seoul, Korea), and the Real-Q M. tuberculosis kit (Biosewoom, Seoul, Korea)

After mixing 3 mL of the specimen sample with an equal amount of 1N NaOH, the samples were vortexed for 30 seconds and then left at room temperature for 15 minutes. Subsequently, the mixture was centrifuged for 20 minutes at 3,000 rpm. After discarding the supernatant, the pellet was mixed with 1 mL of a buffer, vortexed and centrifuged for 5 minutes at 7,000 rpm. This process was repeated three times. Once the supernatant was completely removed, the pellet was dissolved in an adequate amount (50-200 µL) of 5% Chelex100 with a buffer. The sample was then boiled for 10 minutes and centrifuged for 5 minutes at 12,000 rpm. In the final supernatant, 1-2 µL was taken for the PCR reaction.

### The COBAS Amplicor Mycobacterium tuberculosis test and the COBAS TaqMan MTB (Roche Diagnostics, Branchburg, NJ, USA)

One hundred µL of the prepared sample was added to 500 µL of Respiratory Specimen Wash Solution, and this was centrifuged for 10 minutes at 12,500 rpm. After removing the supernatant, 100 µL of Respiratory Specimen Lysis Solution was added and this was vortexed until the pellet was dissolved. The sample was incubated for 45 minutes at 60℃, and then 100 µL of Respiratory Specimen Neutralization Solution was added. Using 50 µL of this reaction mixture with a 50 µL master mix, a PCR reaction was conducted in a reaction tube.

PCR reactions
-------------

The primer sequences used for in-house PCR have previously been described.[@B4] The in-house PCR products were determined to be positive if there was a 285 bp-sized band on the gel electrophoresis ([Fig. 1](#F1){ref-type="fig"}). Using the IS6110 primer, nested PCR was conducted using the GeneAmp PCR system 9600 (Perkin Elmer, CT, USA). For the COBAS Amplicor, which is based on the PCR-hybridization method, Amplicor (Roche Molecular Systems) was used and the sample was determined to be positive if absorbance was equal to or greater than 0.35. In addition, the COBAS TaqMan MTB (Roche, Branchburg, NJ, USA) was used with the COBAS TaqMan 48 Analyzer (Roche), the AdvanSure TB/NTM real-time PCR kit (LG Lifescience, Seoul, Korea) with the SLAN real-time PCR detection system (LG Lifescience), and the Real-Q *M. tuberculosis* kit (Biosewoom, Seoul, Korea) with the Rotor-Gene Q (Corbett Life Science, Sydney, Australia), for the real-time PCR analysis.

The approaches to inconsistent results
--------------------------------------

To solve inconsistent results, the 16S-23S internal transcribed spacer (ITS) was sequenced and the results were confirmed by a BLAST search. In addition, the AdvanSure Mycobacteria Genotyping Chip (LG Lifescience, Seoul, Korea) was used in order to reconfirm the results. The AdvanSure Mycobacteria Genotyping Chip implements the hybridization method by employing the ITS probe that exists between the 16S rRNA and 23S rRNA of mycobacteria, thereby identifying both MTB and NTM. The chip was used according to the manufacturer\'s instructions; hybridization was conducted after PCR and the results were analyzed with the provided insert.

RESULTS
=======

MTB detection
-------------

Out of the 91 clinical samples, there were 75 pulmonary samples (64 sputum samples, 11 BAL samples) and 16 non-pulmonary samples. The results from the two previously implemented PCR methods showed a perfect match for all 91 samples, including the 11 MTB positive samples. These were found to be positive by the other three real-time PCR techniques, and 100% concordance was observed among all the tests ([Table 3](#T3){ref-type="table"}). One of the pulmonary specimens that 5 PCR methods detected MTB showed negative in the TB culture and the acid fast bacilli (AFB) stain. He presented blood-tinged sputum and multiple haziness in the chest X-ray film. Based on clinical manifestation and the PCR result, TB was diagnosed.

NTM detection
-------------

By examining 80 clinical samples that were found to be negative for NTM on at least one test and 37 DNA samples that were provided, we compared the results of the AdvanSure and the Real-Q, which detected NTM. Out of 80 MTB negative samples, one sample was identified as positive by both kits. It was a sputum sample that was later confirmed to contain *M. intracellulare* by subsequent DNA sequencing. For 2 other samples of the 80 samples, the two kits yielded opposite results; the result from AdvenSure was positive while that from Real-Q was negative in both cases ([Table 4](#T4){ref-type="table"}). In one of the pulmonary specimens with NTM negative results by 2 PCR methods showed positive in the culture and the AFB stain. It was then identified to be *M. abscessus* by PCR-restriction fragment length polymorphism (RFLP) in the reference laboratory.[@B6]

These clinical samples were further analyzed through DNA sequencing, genotyping chip tests, AFB stains, and cultures. Interestingly, it was concluded that one sample was NTM false positive by AdvanSure, while the other sample was NTM false negative by the Real-Q (*M. intracellulare*)([Table 4](#T4){ref-type="table"}). Therefore, two samples out of 80 clinical samples that were MTB negative were found to be NTM positive, representing 2.5% of the total samples ([Fig. 2](#F2){ref-type="fig"}). In the chart review, these two patients were confirmed to have NTM TB as well.

The 37 DNA samples provided by LG Lifescience were used to evaluate these two kits by blind testing. Because both kits showed negative for all 6 non-NTM DNA samples, there were no false positive results. Nevertheless, there was one false negative by the Real-Q, which was negative for *M. lentiflavum*.

DISCUSSION
==========

Considering the fact that many laboratories have recently implemented real-time PCR assays to detect viruses or fastidious microbes, and that real-time PCR uses a closed system, thereby lowering the potential for false positive results caused by cross-contamination of the amplified products, it is highly expected that the usage of real-time PCR will continue to increase in the field of microbiological diagnosis.[@B7]-[@B9] In addition, the need to differentiate MTB and NTM is gaining more importance, owing to the growing occurrence of NTMs and the fact that both MTB and NTM require different medications.[@B2] In the present study, therefore, we compared and assessed the diagnostic performance of three types of commercial real-time PCR kits for MTB detection and NTM differentiation, as well as two PCR methods previously implemented in our hospital.

Since the COBAS Amplicor test was shown to have a low sensitivity for non-respiratory samples, Kyung Hee University Medical Center had been using the Amplicor for respiratory samples while in-house PCR was used for non-respiratory samples.[@B10] In our previous reports, the diagnostic sensitivity and specificity of our in-house PCR method were shown to be 81.0% and 99.6%, respectively.[@B11] For the COBAS Amplicor, the diagnostic sensitivity varies from about 70% to about 80%-90%, depending on the studies.[@B11],[@B12] One study in Korea showed the sensitivity and the specificity of the AdvanSure to be 97.9% and 100%, respectively, whereas 91% and 87%, respectively, in the other study, although there are only a fewer reports on the sensitivity and specificity of TB detection by real-time PCR.[@B12],[@B13] These two studies are different in their sample composition; the former used only respiratory samples that comprised sputum and bronchoalveolar lavage (BAL), while the latter included non-respiratory samples such as body fluid and urine, which made up 30.5% of the sample group.[@B13],[@B14] Therefore, it is highly possible that one of the causes for the different estimates of sensitivity and specificity is the difference in the sample composition. In particular, PCR inhibitory materials in non-respiratory samples can result in a lower sensitivity when performing real-time PCR on those samples.[@B15],[@B16]

We found a 100% match of the results for MTB detection in a comparative analysis of five PCR methods, as well as several discordant results with culture and AFB stain. In one of the sputum specimens which showed MTB positive in five PCR methods, MTB did not grow and AFB stain revealed no acid fast bacili. Because the patient had the medical history of TB and showed clinical symptoms and signs to be compatible with active TB, the medication for MTB was started based on the PCR result.

There were also a few discrepant results regarding the detection of NTM. After detecting NTM in the MTB PCR-negative clinical samples with the AdvanSure and the Real-Q, two cases showed mismatching results, while one other case turned out to be positive with both kits. In the two mismatching cases, the results from the AdvanSure were all positive and the results from the Real-Q were all negative. The medical records indicated that one of 2 AdvanSure positive cases showed a history of NTM TB treatment, and the offending organism was later identified to be *M. intracellulare* by DNA sequencing and genotyping chip tests. The other AdvanSure positive case turned out to be TB false positive after additional analysis, thus concluding that there was one false positive result by the AdvanSure and one false negative result by the Real-Q. The false positive sample in the AdvanSure was a sputum sample from a 13-year-old male patient who had a history of TB before the age of 1 and he had undergone a 6-month medication. That patient was hospitalized for symptoms of pneumonia, and his sputum test was negative after an AFB stain. Since the patient did not have clinical evidence of TB, he was released after being treated for bacterial pneumonia. The Ct value for this sample was 33.25, which was higher than 27.02 of the internal control. The sample that turned out to be false negative in the Real-Q was a sputum sample that continuously indicated a positive value of 2+ to 3+ in AFB stain and the offending organism had been identified as *M. intracellulare* by culture. Both samples came from patients who were diagnosed with NTM-caused TB, with both being identified as *M. intracellulare* and the 2 samples were found negative by the TaqMan. Among NTM PCR-negative samples in the AdvanSure and the Real-Q, there was a sputum specimen that showed positive in the culture and the AFB stain. We referred the NTM identification to the reference laboratory, and it was identified to be *M. abscessus*.[@B6] In conclusion, three NTM true-positive results out of 80 MTB negative samples (2.5%) were confirmed. As for 37 DNA samples, the AdvanSure and the Real-Q recognized 6 non-NTM DNA (MTB, nocardial and rhodococcal DNA) as negative, while the Real-Q recognized *M. lentiflavum* as negative out of 31 NTM DNA samples. Considering these results, the implementation of real-time PCR methods that are capable of NTM differentiation made it possible to make a swift and accurate diagnosis of NTM TB.

In conclusion, the five kits included in this comparative analysis yielded good matching ratios for the MTB detection results. However, for detecting NTM, there was some discordance, therefore, further confirmatory measures such as DNA sequencing, a medical record review, and/or culture are required in order to make an accurate diagnosis. Future research on this topic is certainly needed, and this research would be benefited from the putatively increased NTM detection capacities to assess numerous and varied samples, including non-respiratory samples or negative samples in ATB stain.
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![In-house MTB PCR. Lane 1, size marker; Lane 2, internal control; Lane 7, positive; Lane 3-6, 8, negative. MTB, *Mycobacterium tuberculosis*.](ymj-52-301-g001){#F1}

![Two discrepant cases reaffirmed by sequencing and using the AdvanSure Mycobacteria Genotyping Chip (LG Life science, Seoul, Korea). (A) For 37 DNA samples provided, the AdvanSure kit detected all mycobacterial species and Real-Q kit showed a negative result for *M. lentiflavum* (target sequence; IS6110 region). (B) In contrast with the one false positive result from the AdvanSure kit, the Real-Q missed one true positive *M. intracellulare* in the clinical samples (target sequence; 16S-23S internal transcribed spacer region).](ymj-52-301-g002){#F2}

###### 

The Kinds of *Mycobacterium* Species in NTM DNA Specimens

![](ymj-52-301-i001)

NTM, non-tuberculous mycobacterium.

###### 

The Composition of Clinical Specimens

![](ymj-52-301-i002)

MTB, *Mycobacterium tuberculosis*; SP, sputum; BW, bronchial washing.

^\*^Blood, body fluid, urine and tissue.

^†^5 MTB PCR results show complete concordant results; in-house PCR protocol, the COBAS Amplicor MTB, the COBAS TaqMan MTB, the AdvanSure TB/NTM real-time PCR, the Real-Q *M. tuberculosis* kit.

###### 

The MTB PCR Results for 91 Clinical Specimens

![](ymj-52-301-i003)

MTB, *Mycobacterium tuberculosis*; AFB, acid fast bacilli.

^\*^COBAS Amplicor MTB (Roche, Indianapolis, IN, USA).

^†^COBAS TaqMan MTB (Roche, USA).

^‡^AdvanSure TB/NTM real-time PCR kit (LG Lifescience, Seoul, Korea).

^§^Real-Q *M. tuberculosis* kit (Biosewoom, Seoul, Korea).

^∥^One of the 91 clinical samples had no culture and AFB stain results.

###### 

Discrepant Cases for Both the Clinical Specimens and the DNA Samples Provided

![](ymj-52-301-i004)

AFB, acid fast bacilli; TP, true positive; FP, false positive; NTM, non-tuberculous mycobacterium; MIC, *M. intracellulare*; MLF, *M. lentiflavum*.

^\*^It was confirmed to *M. abscessus*.

^†^AdvanSure Mycobacteria Genotyping Chip (LG Lifescience, Seoul, Korea).
